Emergent BioSolutions
(NYSE) EBS
Emergent BioSolutions Financials at a Glance
Market Cap
$427.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$676.80M
Net Income (TTM)
-$8.60M
EPS (TTM)
-$0.28
P/E Ratio
-29.28
Dividend
$0.00
Beta (Volatility)
1.76 (High)
Dividend
$0.00
Beta (Volatility)
1.76 (High)
Price
$8.17
Volume
300,422.441
Open
$8.24
Price
$8.17
Volume
300,422.441
Open
$8.24
Previous Close
$8.28
Daily Range
$8.16 - $8.30
52-Week Range
$5.62 - $14.06
Estimated Earnings Date
Aug 5, 2026
Dividend
$0.00
Beta (Volatility)
1.76 (High)
Price
$8.17
Volume
300,422.441
Open
$8.24
Previous Close
$8.28
Daily Range
$8.16 - $8.30
52-Week Range
$5.62 - $14.06
Estimated Earnings Date
Aug 5, 2026
EBS News
EBS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Emergent BioSolutions
Industry
Biotechnology
Sector
Health CareEmployees
900
CEO
Joseph C. Papa, MBA
Website
www.emergentbiosolutions.comHeadquarters
Gaithersburg, MD 20879, US
EBS Financials
Key Financial Metrics (TTM)
Gross Margin
44.44%
Operating Margin
10.52%
Net Income Margin
-1.27%
Return on Equity
-1.59%
Return on Capital
10.07%
Return on Assets
-0.65%
Earnings Yield
-3.42%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$427.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
51.60M
Volume
300.42K
Avg. Volume
806.12K
Financials (TTM)
Gross Profit
$300.80M
Operating Income
$71.20M
EBITDA
$154.50M
Operating Cash Flow
$148.00M
Capital Expenditure
-$12.60M
Free Cash Flow
$135.40M
Cash & ST Invst.
$160.30M
Total Debt
$573.60M
Emergent BioSolutions Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$156.10M
-29.7%
Gross Profit
$67.60M
-42.0%
Gross Margin
43.31%
N/A
Market Cap
$427.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$474.69K
N/A
Employees
900
N/A
Net Income
$6.80M
-90.0%
EBITDA
$48.50M
-63.6%
Quarterly Fundamentals
Total Cash
$160.30M
+7.5%
Total Debt
$573.60M
-13.8%
Accounts Receivable
$121.60M
-40.3%
Inventory
$327.60M
+4.3%
Long Term Debt
$573.60M
-13.8%
Short Term Debt
$0.00
N/A
Return on Assets
-0.65%
N/A
Return on Invested Capital
6.08%
N/A
Free Cash Flow
-$36.20M
-144.6%
Operating Cash Flow
-$33.80M
-201.8%